In summary, the potential mechanism by which GALNT5 affects FOLFIRINOX chemotherapy resistance in pancreatic cancer may be that it affects the HR repair process of DSB during chemotherapy. This evidence concerns the gene GALNT5 and familial pancreatic carcinoma.